Why the study?
The study investigated changes in antioxidant paraoxonase-1 activity in prostate cancer patients undergoing radiotherapy and its relationship with cancer advancement.
Does radiotherapy alter serum paraoxonase-1 (PON1) activity in patients with prostate cancer?
Does radiotherapy alter serum paraoxonase-1 (PON1) activity in patients with prostate cancer?
Radiotherapy significantly decreases serum PON1 activity in prostate cancer patients, suggesting it could serve as a measure of irradiation efficacy.
PON1 decline after prostate radiotherapy should not yet change practice; hypothesis-generating for its PSA-correlated biomarker role.
We investigated changes in the activity of antioxidant paraoxonase-1 (PON1) in patients with prostate cancer (PCa) undergoing radiotherapy (RT), as well as the relationship of the PON1 activity with the degree of PCa advancement. We included 84 men with PCa. Blood samples were obtained before irradiation and after the completion of RT. The control group was composed of 60 healthy men. There was no significant difference in the PON1 activity between the control group and patients pre-radiotherapy. Irradiation was associated with a significant decrease in the PON1 activity; thus, it could be a measure of the efficacy of RT. No significant correlations between the PON1 activity and Gleason score, prostate volume, BMI (body mass index), or adipose tissue thickness were found. However, there was a positive correlation between the PON1 activity and the PSA concentration in the group of PCa patients.
No takes yet. Share an insight, caveat, or question.
Olszewska−Słonina et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: